Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizia Popoli

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|July 5, 2022
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022Chiara Sacco, Martina Del Manso, Alberto Mateo-Urdiales, et al.
Vaccine|November 18, 2022
Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort studyMassimo Fabiani, Alberto Mateo-Urdiales, Chiara Sacco, et al.
Aging Cell|October 23, 2012
NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic modelSylvie Burnouf, Alberto Martire, Maxime Derisbourg, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Natalizumab: a country-based surveillance programGian Luigi Mancardi, Maria Pia Amato, Roberto D'Alessandro, et al.
Contemporary Clinical Trials|October 8, 2020
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocolMaria Carmela Piccirillo, Paolo Ascierto, Luigi Atripaldi, et al.
BMJ (Clinical Research Ed.)|February 11, 2022
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort studyMassimo Fabiani, Maria Puopolo, Cristina Morciano, et al.
Expert Review of Vaccines|April 7, 2022
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021Massimo Fabiani, Maria Puopolo, Antonietta Filia, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Claudio Jommi, Giovanni Apolone, Giovanna Scroccaro, et al.
BMJ Oncology|June 23, 2025
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)Alberto Puccini, Giuseppe Viscardi, Oriana Ciani, et al.
Journal of Translational Medicine|October 22, 2021
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trialFrancesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|July 5, 2022
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022Chiara Sacco, Martina Del Manso, Alberto Mateo-Urdiales, et al.
Vaccine|November 18, 2022
Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort studyMassimo Fabiani, Alberto Mateo-Urdiales, Chiara Sacco, et al.
Aging Cell|October 23, 2012
NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic modelSylvie Burnouf, Alberto Martire, Maxime Derisbourg, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Natalizumab: a country-based surveillance programGian Luigi Mancardi, Maria Pia Amato, Roberto D'Alessandro, et al.
Contemporary Clinical Trials|October 8, 2020
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocolMaria Carmela Piccirillo, Paolo Ascierto, Luigi Atripaldi, et al.
BMJ (Clinical Research Ed.)|February 11, 2022
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort studyMassimo Fabiani, Maria Puopolo, Cristina Morciano, et al.
Expert Review of Vaccines|April 7, 2022
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021Massimo Fabiani, Maria Puopolo, Antonietta Filia, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Claudio Jommi, Giovanni Apolone, Giovanna Scroccaro, et al.
BMJ Oncology|June 23, 2025
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)Alberto Puccini, Giuseppe Viscardi, Oriana Ciani, et al.
Journal of Translational Medicine|October 22, 2021
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trialFrancesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Pageof 10